{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:11:27Z","timestamp":1788174687434,"version":"build-2803163510"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases,United States","award":["R56AI175016"],"award-info":[{"award-number":["R56AI175016"]}]},{"name":"National Institute of Allergy and Infectious Diseases,United States","award":["R01AI176999"],"award-info":[{"award-number":["R01AI176999"]}]},{"name":"National Institute of Allergy and Infectious Diseases,United States","award":["K23AI182453"],"award-info":[{"award-number":["K23AI182453"]}]},{"name":"Australian Research Council Industrial Transformation Research Hub Grant","award":["IH190100021"],"award-info":[{"award-number":["IH190100021"]}]},{"name":"Australian Research Council Industrial Transformation Research Hub Grant","award":["IH190100021"],"award-info":[{"award-number":["IH190100021"]}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1173361"],"award-info":[{"award-number":["APP1173361"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Allergy and Infectious Diseases,United States,","award":["R01AI177002"],"award-info":[{"award-number":["R01AI177002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11904-025-00722-7","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T21:53:25Z","timestamp":1737755605000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Antimicrobial Resistance in Curable Sexually Transmitted Infections"],"prefix":"10.1007","volume":"22","author":[{"given":"Lorenzo","family":"Giacani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona S.","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Muzny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keonte J.","family":"Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Pasricha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lao-Tzu","family":"Allan-Blitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"722_CR1","unstructured":"Organization WH. Global progress report on HIV, viral hepatitis and sexually transmitted infections. https:\/\/www.who.int\/publications\/i\/item\/9789240027077. 2021."},{"issue":"3","key":"722_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1128\/CMR.00010-14","volume":"27","author":"M Unemo","year":"2014","unstructured":"Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587\u2013613.","journal-title":"Clin Microbiol Rev"},{"key":"722_CR3","doi-asserted-by":"publisher","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Report. Atlanta, GA. 2019. https:\/\/doi.org\/10.15620\/cdc:82532","DOI":"10.15620\/cdc:82532"},{"key":"722_CR4","unstructured":"World Health Organization. Global Priority List of Antibiotic-Resistant Bacteria [press release]. 2017.\u00a0Available at: https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed 28 Jun 2024."},{"key":"722_CR5","unstructured":"World Health Organization. WHO Bacterial Priority Pathogens List. 2024. Available at: https:\/\/iris.who.int\/bitstream\/handle\/10665\/376776\/9789240093461-eng.pdf?sequence=1 Accessed June 28, 2024."},{"issue":"4","key":"722_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.idc.2013.08.004","volume":"27","author":"C Mitchell","year":"2013","unstructured":"Mitchell C, Prabhu M. Pelvic inflammatory disease: Current concepts in pathogenesis, diagnosis and treatment. Infect Dis Clin North Am. 2013;27(4):793\u2013809.","journal-title":"Infect Dis Clin North Am"},{"issue":"1","key":"722_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajog.2016.08.008","volume":"216","author":"DG Tsevat","year":"2017","unstructured":"Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and infertility. Am J Obstet Gynecol. 2017;216(1):1\u20139.","journal-title":"Am J Obstet Gynecol"},{"key":"722_CR8","doi-asserted-by":"publisher","first-page":"30184","DOI":"10.1155\/IDOG\/2006\/30184","volume":"2006","author":"CL Haggerty","year":"2006","unstructured":"Haggerty CL, Totten PA, Astete SG, Ness RB. Mycoplasma genitalium among women with nongonococcal, nonchlamydial pelvic inflammatory disease. Infect Dis Obstet Gynecol. 2006;2006:30184.","journal-title":"Infect Dis Obstet Gynecol"},{"key":"722_CR9","doi-asserted-by":"publisher","first-page":"959816","DOI":"10.1155\/2011\/959816","volume":"2011","author":"CL Haggerty","year":"2011","unstructured":"Haggerty CL, Taylor BD. Mycoplasma genitalium: an emerging cause of pelvic inflammatory disease. Infect Dis Obstet Gynecol. 2011;2011:959816.","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"2","key":"722_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.idc.2023.02.009","volume":"37","author":"GE Wood","year":"2023","unstructured":"Wood GE, Bradshaw CS, Manhart LE. Update in epidemiology and management of mycoplasma genitalium infections. Infect Dis Clin North Am. 2023;37(2):311\u201333.","journal-title":"Infect Dis Clin North Am"},{"key":"722_CR11","doi-asserted-by":"publisher","first-page":"ciae295","DOI":"10.1093\/cid\/ciae295","volume":"7","author":"K Htaik","year":"2024","unstructured":"Htaik K, Vodstrcil LA, Plummer EL, Sfameni AM, Machalek DA, Manhart LE, et al. Systematic review and meta-analysis of the association between mycoplasma genitalium and pelvic inflammatory disease (PID). Clin Infect Dis. 2024;7:ciae295. https:\/\/doi.org\/10.1093\/cid\/ciae295.","journal-title":"Clin Infect Dis."},{"key":"722_CR12","doi-asserted-by":"publisher","first-page":"106693","DOI":"10.1016\/j.actatropica.2022.106693","volume":"236","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Li Y, Lu H, Li D, Zhang R, Xie X, et al. A systematic review of the correlation between Trichomonas vaginalis infection and infertility. Acta Trop. 2022;236:106693.","journal-title":"Acta Trop"},{"issue":"12","key":"722_CR13","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1111\/1471-0528.16774","volume":"128","author":"OT Van Gerwen","year":"2021","unstructured":"Van Gerwen OT, Craig-Kuhn MC, Jones AT, Schroeder JA, Deaver J, Buekens P, et al. Trichomoniasis and adverse birth outcomes: A systematic review and meta-analysis. BJOG. 2021;128(12):1907\u201315.","journal-title":"BJOG"},{"issue":"3","key":"722_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/cid\/civ312","volume":"61","author":"R Lis","year":"2015","unstructured":"Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: A meta-analysis. Clin Infect Dis. 2015;61(3):418\u201326.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"722_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1056\/NEJMra2202762","volume":"390","author":"IA Stafford","year":"2024","unstructured":"Stafford IA, Workowski KA, Bachmann LH. Syphilis complicating pregnancy and congenital Syphilis. N Engl J Med. 2024;390(3):242\u201353.","journal-title":"N Engl J Med"},{"key":"722_CR16","doi-asserted-by":"publisher","first-page":"9315757","DOI":"10.1155\/2016\/9315757","volume":"2016","author":"K Adachi","year":"2016","unstructured":"Adachi K, Nielsen-Saines K, Klausner JD. Chlamydia trachomatis infection in pregnancy: The global challenge of preventing adverse pregnancy and infant outcomes in sub-saharan Africa and Asia. Biomed Res Int. 2016;2016:9315757.","journal-title":"Biomed Res Int"},{"issue":"3","key":"722_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/antibiotics7030059","volume":"7","author":"V Dolange","year":"2018","unstructured":"Dolange V, Churchward CP, Christodoulides M, Snyder LAS. The growing threat of gonococcal blindness. Antibiot (Basel). 2018;7(3):59. https:\/\/doi.org\/10.3390\/antibiotics7030059.","journal-title":"Antibiot (Basel)"},{"key":"722_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejogrb.2018.06.031","volume":"228","author":"S Yang","year":"2018","unstructured":"Yang S, Zhao W, Wang H, Wang Y, Li J, Wu X. Trichomonas vaginalis infection-associated risk of cervical cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2018;228:166\u201373.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"10078","key":"722_CR19","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(16)32411-4","volume":"389","author":"EW Hook","year":"2017","unstructured":"Hook EW 3. Syphilis Lancet. 2017;389(10078):1550\u20137.","journal-title":"Syphilis Lancet"},{"issue":"1","key":"722_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrmicro794","volume":"2","author":"SR Galvin","year":"2004","unstructured":"Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004;2(1):33\u201342.","journal-title":"Nat Rev Microbiol"},{"issue":"6","key":"722_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/OLQ.0000000000000980","volume":"46","author":"J Jones","year":"2019","unstructured":"Jones J, Weiss K, Mermin J, Dietz P, Rosenberg ES, Gift TL, et al. Proportion of Incident Human Immunodeficiency Virus cases among men who have sex with men attributable to gonorrhea and chlamydia: A modeling analysis. Sex Transm Dis. 2019;46(6):357\u201363.","journal-title":"Sex Transm Dis"},{"issue":"7","key":"722_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/sextrans-2020-054706","volume":"97","author":"MY Wu","year":"2021","unstructured":"Wu MY, Gong HZ, Hu KR, Zheng HY, Wan X, Li J. Effect of syphilis infection on HIV acquisition: a systematic review and meta-analysis. Sex Transm Infect. 2021;97(7):525\u201333.","journal-title":"Sex Transm Infect"},{"issue":"12","key":"722_CR23","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1473-3099(17)30405-X","volume":"17","author":"KJ Looker","year":"2017","unstructured":"Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017;17(12):1303\u201316.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"722_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/sextrans-2018-053713","volume":"95","author":"SC Masha","year":"2019","unstructured":"Masha SC, Cools P, Sanders EJ, Vaneechoutte M, Crucitti T. Trichomonas vaginalis and HIV infection acquisition: A systematic review and meta-analysis. Sex Transm Infect. 2019;95(1):36\u201342.","journal-title":"Sex Transm Infect"},{"issue":"6","key":"722_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/OLQ.0000000000001601","volume":"49","author":"EK Barker","year":"2022","unstructured":"Barker EK, Malekinejad M, Merai R, Lyles CM, Sipe TA, DeLuca JB, et al. Risk of human immunodeficiency virus acquisition among high-risk heterosexuals with nonviral sexually transmitted infections: A systematic review and meta-analysis. Sex Transm Dis. 2022;49(6):383\u201397.","journal-title":"Sex Transm Dis"},{"issue":"4","key":"722_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/OLQ.0000000000000725","volume":"45","author":"HW Chesson","year":"2018","unstructured":"Chesson HW, Kirkcaldy RD, Gift TL, Owusu-Edusei K Jr, Weinstock HS. An illustration of the potential health and economic benefits of combating antibiotic-resistant gonorrhea. Sex Transm Dis. 2018;45(4):250\u20133.","journal-title":"Sex Transm Dis"},{"issue":"Suppl 1","key":"722_CR27","doi-asserted-by":"publisher","first-page":"A365","DOI":"10.1136\/sextrans-2013-051184.1140","volume":"89","author":"H Chesson","year":"2013","unstructured":"Chesson H, Owusu-Edusei K, Kirkcaldy RD, Gift TL, Weinstock HS. P5.096\u2005estimating the potential economic impact of Antimicrobial Resistance in <\u2009em\u2009>\u2009neisseria gonorrhoeae in the United States. Sex Transm Infect. 2013;89(Suppl 1):A365\u2013A.","journal-title":"Sex Transm Infect"},{"issue":"4","key":"722_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","volume":"70","author":"KA Workowski","year":"2021","unstructured":"Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infections treatment guidelines. MMWR Recomm Rep. 2021;70(4):1\u2013187.","journal-title":"MMWR Recomm Rep"},{"key":"722_CR29","unstructured":"World Health Organization. Guidelines for the management of symptomatic sexually transmitted infections. WHO Guidelines. Geneva 2021.\u00a0Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34370424. Accessed 28 Jun 2024."},{"issue":"3","key":"722_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/JD9.0000000000000072","volume":"3","author":"Q-Q Wang","year":"2020","unstructured":"Wang Q-Q, Zhang R-L, Liu Q-Z, Xu J-H, Su X-H, Yin Y-P, et al. National guidelines on diagnosis and treatment of Gonorrhea in China (2020)#. Int J Dermatology Venereol. 2020;3(3):129\u201334.","journal-title":"Int J Dermatology Venereol"},{"issue":"1","key":"722_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/0956462419886775","volume":"31","author":"H Fifer","year":"2020","unstructured":"Fifer H, Saunders J, Soni S, Sadiq ST, FitzGerald M. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae. Int J STD AIDS. 2020;31(1):4\u201315.","journal-title":"Int J STD AIDS"},{"key":"722_CR32","doi-asserted-by":"publisher","first-page":"956462420949126","DOI":"10.1177\/0956462420949126","volume":"29","author":"M Unemo","year":"2020","unstructured":"Unemo M, Ross J, Serwin AB, Gomberg M, Cusini M, Jensen JS. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2020;29:956462420949126.https:\/\/doi.org\/10.1177\/0956462420949126","journal-title":"Int J STD AIDS"},{"key":"722_CR33","unstructured":"Recommendations for treatment of gonococcal, infections in the era of mdr\/xdr gonorrhoe a (document for sexual health and infectious disease specialists). 2019. Available at: https:\/\/ashm.org.au\/wp-content\/uploads\/2023\/08\/ASHM-Website_CDNA_xdrgonorrhoea_recommendations.pdf Accessed December 23, 2023."},{"issue":"3","key":"722_CR34","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/gb-2008-9-3-r60","volume":"9","author":"TJ Treangen","year":"2008","unstructured":"Treangen TJ, Ambur OH, Tonjum T, Rocha EP. The impact of the neisserial DNA uptake sequences on genome evolution and stability. Genome Biol. 2008;9(3):R60.","journal-title":"Genome Biol"},{"issue":"9","key":"722_CR35","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S1473-3099(23)00479-6","volume":"23","author":"V Ouk","year":"2023","unstructured":"Ouk V, Pham CD, Wi T, van Hal SJ, Lahra MM, group ECw. The enhanced gonococcal surveillance programme, Cambodia. Lancet Infect Dis. 2023;23(9):e332\u20133.","journal-title":"Lancet Infect Dis"},{"issue":"46","key":"722_CR36","doi-asserted-by":"publisher","first-page":"2200803","DOI":"10.2807\/1560-7917.ES.2022.27.46.2200803","volume":"27","author":"M Day","year":"2022","unstructured":"Day M, Pitt R, Mody N, Saunders J, Rai R, Nori A, et al. Detection of 10 cases of ceftriaxone-resistant neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022. Euro Surveill. 2022;27(46):2200803. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.46.2200803.","journal-title":"Euro Surveill"},{"issue":"24","key":"722_CR37","doi-asserted-by":"publisher","first-page":"2200455","DOI":"10.2807\/1560-7917.ES.2022.27.24.2200455","volume":"27","author":"S Pleininger","year":"2022","unstructured":"Pleininger S, Indra A, Golparian D, Heger F, Schindler S, Jacobsson S, et al. Extensively drug-resistant (XDR) neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. Euro Surveill. 2022;27(24):2200455. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.24.2200455.","journal-title":"Euro Surveill"},{"issue":"2","key":"722_CR38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3201\/eid2402.171756","volume":"24","author":"B Lefebvre","year":"2018","unstructured":"Lefebvre B, Martin I, Demczuk W, Deshaies L, Michaud S, Labbe AC, et al. Ceftriaxone-resistant neisseria gonorrhoeae, Canada, 2017. Emerg Infect Dis. 2018;24(2):381\u20133.","journal-title":"Emerg Infect Dis"},{"issue":"42","key":"722_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2807\/1560-7917.ES.2017.22.42.17-00659","volume":"22","author":"D Terkelsen","year":"2017","unstructured":"Terkelsen D, Tolstrup J, Johnsen CH, Lund O, Larsen HK, Worning P, et al. Multidrug-resistant Neisseria gonorrhoeae infection with ceftriaxone resistance and intermediate resistance to azithromycin, Denmark, 2017. Euro Surveill. 2017;22(42):17\u201300659.https:\/\/doi.org\/10.2807\/1560-7917.ES.2017.22.42.17-00659","journal-title":"Euro Surveill"},{"issue":"4","key":"722_CR40","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3201\/eid2404.171873","volume":"24","author":"MM Lahra","year":"2018","unstructured":"Lahra MM, Martin I, Demczuk W, Jennison AV, Lee KI, Nakayama SI, et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant neisseria gonorrhoeae strain. Emerg Infect Dis. 2018;24(4):735\u201340.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"722_CR41","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/S1473-3099(23)00785-5","volume":"24","author":"JL Reimche","year":"2024","unstructured":"Reimche JL, Pham CD, Joseph SJ, Hutton S, Cartee JC, Ruan Y, et al. Novel strain of multidrug non-susceptible Neisseria gonorrhoeae in the USA. Lancet Infect Dis. 2024;24(3):e149\u201351.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"722_CR42","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1128\/AAC.00325-11","volume":"55","author":"M Ohnishi","year":"2011","unstructured":"Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011;55(7):3538\u201345.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"722_CR43","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1128\/AAC.05760-11","volume":"56","author":"M Unemo","year":"2012","unstructured":"Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56(3):1273\u201380.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"722_CR44","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/jac\/dks162","volume":"67","author":"J Camara","year":"2012","unstructured":"Camara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, et al. Molecular characterization of two high-level ceftriaxone-resistant neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012;67(8):1858\u201360.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"722_CR45","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1128\/AAC.00504-16","volume":"60","author":"S Nakayama","year":"2016","unstructured":"Nakayama S, Shimuta K, Furubayashi K, Kawahata T, Unemo M, Ohnishi M. New ceftriaxone- and multidrug-resistant neisseria gonorrhoeae strain with a novel mosaic penA gene isolated in Japan. Antimicrob Agents Chemother. 2016;60(7):4339\u201341.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"722_CR46","doi-asserted-by":"publisher","first-page":"255","DOI":"10.15585\/mmwr.mm7312a2","volume":"73","author":"X Zhu","year":"2024","unstructured":"Zhu X, Xi Y, Gong X, Chen S. Ceftriaxone-resistant gonorrhea - China, 2022. MMWR Morb Mortal Wkly Rep. 2024;73(12):255\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"722_CR47","doi-asserted-by":"publisher","first-page":"dlae053","DOI":"10.1093\/jacamr\/dlae053","volume":"6","author":"V Ouk","year":"2024","unstructured":"Ouk V, Heng LS, Virak M, Deng S, Lahra MM, Frankson R, et al. High prevalence of ceftriaxone-resistant and XDR Neisseria gonorrhoeae in several cities of Cambodia, 2022-23: WHO enhanced gonococcal antimicrobial surveillance programme (EGASP). JAC Antimicrob Resist. 2024;6(2):dlae053.","journal-title":"JAC Antimicrob Resist"},{"key":"722_CR48","first-page":"101125","volume":"48","author":"PT Lan","year":"2024","unstructured":"Lan PT, Nguyen HT, Golparian D, Thuy Van NT, Maatouk I, Unemo M, et al. The WHO enhanced gonococcal antimicrobial surveillance programme (EGASP) identifies high levels of ceftriaxone resistance across Vietnam, 2023. Lancet Reg Health West Pac. 2024;48:101125.","journal-title":"Lancet Reg Health West Pac"},{"issue":"9","key":"722_CR49","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1016\/S1473-3099(24)00486-9","volume":"24","author":"SJ van Hal","year":"2024","unstructured":"van Hal SJ, Sherry N, Coombs G, Mowlaboccus S, Whiley DM, Lahra MM. Emergence of an extensively drug-resistant Neisseria gonorrhoeae clone. Lancet Infect Dis. 2024;24(9):e547\u20138.","journal-title":"Lancet Infect Dis"},{"key":"722_CR50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-1-4939-9496-0_3","volume":"1997","author":"M Unemo","year":"2019","unstructured":"Unemo M, Golparian D, Eyre DW. Antimicrobial resistance in neisseria gonorrhoeae and treatment of gonorrhea. Methods Mol Biol. 2019;1997:37\u201358.","journal-title":"Methods Mol Biol"},{"issue":"25","key":"722_CR51","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMc1512757","volume":"374","author":"H Fifer","year":"2016","unstructured":"Fifer H, Natarajan U, Jones L, Alexander S, Hughes G, Golparian D, et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med. 2016;374(25):2504\u20136.","journal-title":"N Engl J Med"},{"issue":"27","key":"722_CR52","doi-asserted-by":"publisher","first-page":"1800323","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","volume":"23","author":"DW Eyre","year":"2018","unstructured":"Eyre DW, Sanderson ND, Lord E, Regisford-Reimmer N, Chau K, Barker L, et al. Gonorrhoea treatment failure caused by a neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill. 2018;23(27):1800323. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018.23.27.1800323.","journal-title":"Euro Surveill"},{"issue":"12","key":"722_CR53","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1086\/648428","volume":"49","author":"H Weinstock","year":"2009","unstructured":"Weinstock H, Workowski KA. Pharyngeal gonorrhea: an important reservoir of infection? Clin Infect Dis. 2009;49(12):1798\u2013800.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"722_CR54","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2217\/fmb.12.117","volume":"7","author":"M Unemo","year":"2012","unstructured":"Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol. 2012;7(12):1401\u201322.","journal-title":"Future Microbiol"},{"issue":"4","key":"722_CR55","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1542\/peds.2004-2294","volume":"116","author":"JL Blumer","year":"2005","unstructured":"Blumer JL, Reed MD, Kaplan EL, Drusano GL. Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group a streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling. Pediatrics. 2005;116(4):927\u201332.","journal-title":"Pediatrics"},{"issue":"1","key":"722_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11904-024-00709-w","volume":"22","author":"LT Allan-Blitz","year":"2024","unstructured":"Allan-Blitz LT, Mayer KH. Doxycycline Post-exposure Prophylaxis for bacterial sexually transmitted infections: The current landscape and future directions. Curr HIV\/AIDS Rep. 2024;22(1):1.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"25","key":"722_CR57","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2304007","volume":"389","author":"J Stewart","year":"2023","unstructured":"Stewart J, Oware K, Donnell D, Violette LR, Odoyo J, Soge OO, et al. Doxycycline prophylaxis to prevent sexually transmitted infections in women. N Engl J Med. 2023;389(25):2331\u201340.","journal-title":"N Engl J Med"},{"key":"722_CR58","unstructured":"Molina J, Bercot B, Assoumou L, Michele AG, Rubenstein E, Pialoux G, Katlama C, Sugers L, Bebear C, Dupin N, Viard JP, Pavie J, Duvivier C, Ghosn J, Costagliola D, Anrs 174 doxyvac: An open-label randomized trial to prevent stis in msm on prep. Presented at the conference on retroviruses and opportunistic infections. February 19\u201322 2023, Seattle Washington. Abstract Available at: https:\/\/www.croiconference.org\/abstract\/anrs-174-doxyvac-an-open-label-randomized-trial-to-prevent-stis-in-msm-on-prep\/ Accessed April 19, 2024. 2023."},{"issue":"14","key":"722_CR59","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","volume":"388","author":"AF Luetkemeyer","year":"2023","unstructured":"Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med. 2023;388(14):1296\u2013306.","journal-title":"N Engl J Med"},{"key":"722_CR60","doi-asserted-by":"publisher","unstructured":"Chu VT, Glascock A, Donnell D, Grabow C, Brown CE, Ward R, et al. Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome. Nat Med. 2024.https:\/\/doi.org\/10.1038\/s41591-024-03274-2","DOI":"10.1038\/s41591-024-03274-2"},{"issue":"5","key":"722_CR61","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/cid\/ciad279","volume":"77","author":"TD Mortimer","year":"2023","unstructured":"Mortimer TD, Grad YH. A genomic perspective on the near-term impact of doxycycline post-exposure prophylaxis on neisseria gonorrhoeae antimicrobial resistance. Clin Infect Dis. 2023;77(5):788\u201391.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"722_CR62","doi-asserted-by":"publisher","first-page":"e0009423","DOI":"10.1128\/cmr.00094-23","volume":"37","author":"E Williams","year":"2024","unstructured":"Williams E, Seib KL, Fairley CK, Pollock GL, Hocking JS, McCarthy JS, et al. Neisseria gonorrhoeae vaccines: A contemporary overview. Clin Microbiol Rev. 2024;37(1):e0009423.","journal-title":"Clin Microbiol Rev"},{"key":"722_CR63","doi-asserted-by":"publisher","first-page":"jiae383","DOI":"10.1093\/infdis\/jiae383","volume":"31","author":"WE Abara","year":"2024","unstructured":"Abara WE, Kirkcaldy RD, Bernstein KT, Galloway E, Learner ER. Effectiveness of MenB-4C vaccine against gonorrhea: a systematic review and meta-analysis. J Infect Dis. 2024;31:jiae383.https:\/\/doi.org\/10.1093\/infdis\/jiae383","journal-title":"J Infect Dis"},{"issue":"38","key":"722_CR64","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.1016\/j.vaccine.2023.07.048","volume":"41","author":"TN Padeniya","year":"2023","unstructured":"Padeniya TN, Hui BB, Wood JG, Seib KL, Regan DG. The potential impact of a vaccine on Neisseria gonorrhoeae prevalence among heterosexuals living in a high prevalence setting. Vaccine. 2023;41(38):5553\u201361.","journal-title":"Vaccine"},{"key":"722_CR65","unstructured":"Molina J, Bercot B, Assoumou L, Michele AG, Rubenstein E, Pialoux G, Katlama C, Sugers L, Bebear C, Dupin N, Viard JP, Pavie J, Duvivier C, Ghosn J, Costagliola D. Final results of ANRS 174 DOXYVAC: A randomized trial to prevent STI in MSM on PrEP. Presented at the 2024 conference on retroviruses and opportunistic infections. Denver, CO. March 3\u20136, 2024. Available at: https:\/\/www.croiconference.org\/abstract\/final-results-of-anrs-174-doxyvac-a-randomized-trial-to-prevent-sti-in-msm-on-prep\/ Accessed November 4, 2024. 2024."},{"key":"722_CR66","unstructured":"EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments [press release]. 2024.\u00a0Available at:\u00a0 https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/eagle-1-phase-iii-data-show-potential-for-gepotidacin-as-a-new-oral-treatment-option-for-uncomplicated-gc\/. Accessed 28 Jun 2024."},{"key":"722_CR67","unstructured":"Positive results announced in. largest pivotal phase 3 trial of a first-in-class oral antibiotic to treat uncomplicated gonorrhoea. [press release]. 2023.\u00a0Available at: https:\/\/gardp.org\/positive-results-announced-in-largest-pivotal-phase-3-trial-of-a-first-in-class-oral-antibiotic-to-treat-uncomplicated-gonorrhoea\/. Accessed 28 Jun 2024."},{"issue":"1","key":"722_CR68","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cmi.2022.08.008","volume":"29","author":"K Vaezzadeh","year":"2023","unstructured":"Vaezzadeh K, Sepidarkish M, Mollalo A, As\u2019adi N, Rouholamin S, Rezaeinejad M, et al. Global prevalence of Neisseria gonorrhoeae infection in pregnant women: A systematic review and meta-analysis. Clin Microbiol Infect. 2023;29(1):22\u201331.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"722_CR69","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1071\/SH19061","volume":"16","author":"RD Kirkcaldy","year":"2019","unstructured":"Kirkcaldy RD, Weston E, Segurado AC, Hughes G. Epidemiology of gonorrhoea: A global perspective. Sex Health. 2019;16(5):401\u201311.","journal-title":"Sex Health."},{"key":"722_CR70","doi-asserted-by":"publisher","first-page":"851635","DOI":"10.3389\/fmed.2022.851635","volume":"9","author":"L Fu","year":"2022","unstructured":"Fu L, Sun Y, Han M, Wang B, Xiao F, Zhou Y, et al. Incidence trends of five common sexually transmitted infections excluding HIV from 1990 to 2019 at the global, regional, and national levels: Results from the global burden of disease study 2019. Front Med (Lausanne). 2022;9:851635.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"722_CR71","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/cid\/ciy145","volume":"67","author":"SN Taylor","year":"2018","unstructured":"Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA, et al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: A phase 2, randomized, dose-ranging, single-oral dose evaluation. Clin Infect Dis. 2018;67(4):504\u201312.","journal-title":"Clin Infect Dis"},{"issue":"19","key":"722_CR72","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","volume":"379","author":"SN Taylor","year":"2018","unstructured":"Taylor SN, Marrazzo J, Batteiger BE, Hook EW 3, Sena AC, Long J, et al. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med. 2018;379(19):1835\u201345.","journal-title":"N Engl J Med"},{"issue":"9","key":"722_CR73","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/cid\/ciac371","volume":"75","author":"LT Allan-Blitz","year":"2022","unstructured":"Allan-Blitz LT, Adamson PC, Klausner JD. Resistance-guided therapy for neisseria gonorrhoeae. Clin Infect Dis. 2022;75(9):1655\u201360.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"722_CR74","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/OLQ.0000000000000591","volume":"44","author":"LT Allan-Blitz","year":"2017","unstructured":"Allan-Blitz LT, Wang X, Klausner JD, Wild-Type Gyrase A. Genotype of neisseria gonorrhoeae predicts in vitro susceptibility to ciprofloxacin: A systematic review of the literature and meta-analysis. Sex Transm Dis. 2017;44(5):261\u20135.","journal-title":"Sex Transm Dis"},{"issue":"2","key":"722_CR75","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/cid\/ciaa596","volume":"73","author":"JD Klausner","year":"2021","unstructured":"Klausner JD, Bristow CC, Soge OO, Shahkolahi A, Waymer T, Bolan RK, et al. Resistance-guided treatment of Gonorrhea: a prospective clinical study. Clin Infect Dis. 2021;73(2):298\u2013303.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"722_CR76","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/cid\/ciw864","volume":"64","author":"LT Allan-Blitz","year":"2017","unstructured":"Allan-Blitz LT, Humphries RM, Hemarajata P, Bhatti A, Pandori MW, Siedner MJ, et al. Implementation of a rapid genotypic assay to promote targeted ciprofloxacin therapy of neisseria gonorrhoeae in a large health system. Clin Infect Dis. 2017;64(9):1268\u201370.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"722_CR77","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/09564624221147326","volume":"34","author":"J Qquellon","year":"2023","unstructured":"Qquellon J, Vargas SK, Eguiluz M, Vasquez F, Durand D, Allan-Blitz LT, et al. Extra-genital Neisseria gonorrhoeae infections with genetic mutations conferring ciprofloxacin resistance among men who have sex with men and transgender women in Lima, Peru. Int J STD AIDS. 2023;34(4):245\u201350.","journal-title":"Int J STD AIDS"},{"key":"722_CR78","unstructured":"Australasian Society for HIV, Viral hepatitis and sexual health medicine. Australian STI management guidelines for use in primary care: Gonorrhoeae. Available at: https:\/\/sti.guidelines.org.au\/sexually-transmissible-infections\/gonorrhoea\/ Accessed February 3, 2022."},{"issue":"10","key":"722_CR79","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1093\/jac\/dkz292","volume":"74","author":"LT Allan-Blitz","year":"2019","unstructured":"Allan-Blitz LT, Ellis OL, Wee R, Truong A, Ebeyan SM, Tan LY, et al. Improved determination of neisseria gonorrhoeae gyrase a genotype results in clinical specimens. J Antimicrob Chemother. 2019;74(10):2913\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"722_CR80","doi-asserted-by":"publisher","first-page":"e00089","DOI":"10.1128\/JCM.00089-21","volume":"59","author":"DYJ Lee","year":"2021","unstructured":"Lee DYJ, Ashcroft MM, Chow EPF, Sait M, De Petra V, Tschaepe M, et al. Reflex detection of ciprofloxacin resistance in neisseria gonorrhoeae by use of the speedx resistanceplus GC assay. J Clin Microbiol. 2021;59(5):e00089\u201321. https:\/\/doi.org\/10.1128\/JCM.00089-21.","journal-title":"J Clin Microbiol"},{"key":"722_CR81","unstructured":"Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2022: Gonococcal isolate surveillance project profile. April 2024. Available at: https:\/\/www.cdc.gov\/sti-statistics\/media\/pdfs\/2024\/07\/2022-GISP-Profiles_National_CLEARED_CLEAN.pdf Accessed November 1, 2024."},{"issue":"11","key":"722_CR82","doi-asserted-by":"publisher","first-page":"e0206419","DOI":"10.1371\/journal.pone.0206419","volume":"13","author":"P Sirivongrangson","year":"2018","unstructured":"Sirivongrangson P, Girdthep N, Sukwicha W, Buasakul P, Tongtoyai J, Weston E, et al. The first year of the global enhanced Gonococcal antimicrobial surveillance programme (EGASP) in Bangkok, Thailand, 2015\u20132016. PLoS ONE. 2018;13(11):e0206419.","journal-title":"PLoS ONE"},{"issue":"5","key":"722_CR83","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/infdis\/jiz504","volume":"221","author":"X Deng","year":"2020","unstructured":"Deng X, Klausner JD. Six penA codons accurately and reliably predict cefixime-decreased susceptibility in Neisseria gonorrhoeae. J Infect Dis. 2020;221(5):851\u20132.","journal-title":"J Infect Dis"},{"issue":"5","key":"722_CR84","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1071\/SH18227","volume":"16","author":"X Deng","year":"2019","unstructured":"Deng X, Allan-Blitz LT, Klausner JD. Using the genetic characteristics of neisseria gonorrhoeae strains with decreased susceptibility to cefixime to develop a molecular assay to predict cefixime susceptibility. Sex Health. 2019;16(5):488\u201399. https:\/\/doi.org\/10.1071\/SH18227.","journal-title":"Sex Health"},{"issue":"9","key":"722_CR85","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1128\/AAC.00309-10","volume":"54","author":"SA Chisholm","year":"2010","unstructured":"Chisholm SA, Dave J, Ison CA. High-level azithromycin resistance occurs in neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother. 2010;54(9):3812\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"722_CR86","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.3201\/eid2709.204843","volume":"27","author":"RA Gianecini","year":"2021","unstructured":"Gianecini RA, Poklepovich T, Golparian D, Cuenca N, Tuduri E, Unemo M, et al. Genomic epidemiology of azithromycin-nonsusceptible neisseria gonorrhoeae, Argentina, 2005\u20132019. Emerg Infect Dis. 2021;27(9):2369\u201378.","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"722_CR87","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3390\/antibiotics10091027","volume":"10","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Liu J, Chen S, Xu W, Han Y, Yin Y. The accuracy of molecular detection targeting the mutation c2611t for detecting moderate-level azithromycin resistance in neisseria gonorrhoeae: A systematic review and meta-analysis. Antibiot (Basel). 2021;10(9):1027. https:\/\/doi.org\/10.3390\/antibiotics10091027.","journal-title":"Antibiot (Basel)."},{"issue":"3","key":"722_CR88","doi-asserted-by":"publisher","first-page":"e0168821","DOI":"10.1128\/aac.01688-21","volume":"66","author":"P Sawatzky","year":"2022","unstructured":"Sawatzky P, Demczuk W, Lefebvre B, Allen V, Diggle M, Hoang L, et al. Increasing azithromycin resistance in neisseria gonorrhoeae due to NG-MAST 12302 clonal spread in Canada, 2015 to 2018. Antimicrob Agents Chemother. 2022;66(3):e0168821.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"722_CR89","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1016\/S2666-5247(22)00034-9","volume":"3","author":"TD Mortimer","year":"2022","unstructured":"Mortimer TD, Zhang JJ, Ma KC, Grad YH. Loci for prediction of penicillin and tetracycline susceptibility in Neisseria gonorrhoeae: a genome-wide association study. Lancet Microbe. 2022;3(5):e376\u201381.","journal-title":"Lancet Microbe"},{"issue":"12","key":"722_CR90","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1093\/jac\/dkaa360","volume":"75","author":"SW Peterson","year":"2020","unstructured":"Peterson SW, Martin I, Demczuk W, Barairo N, Naidu P, Lefebvre B, et al. Multiplex real-time PCR assays for the prediction of cephalosporin, ciprofloxacin and azithromycin antimicrobial susceptibility of positive Neisseria gonorrhoeae nucleic acid amplification test samples. J Antimicrob Chemother. 2020;75(12):3485\u201390.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"722_CR91","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/infdis\/jiaa495","volume":"223","author":"EY Lin","year":"2021","unstructured":"Lin EY, Adamson PC, Deng X, Klausner JD. Establishing novel molecular algorithms to predict decreased susceptibility to ceftriaxone in neisseria gonorrhoeae strains. J Infect Dis. 2021;223(7):1232\u201340.","journal-title":"J Infect Dis"},{"issue":"5","key":"722_CR92","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1177\/0956462415618837","volume":"27","author":"E Lanjouw","year":"2016","unstructured":"Lanjouw E, Ouburg S, de Vries HJ, Stary A, Radcliffe K, Unemo M. 2015 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS. 2016;27(5):333\u201348.","journal-title":"Int J STD AIDS"},{"issue":"4","key":"722_CR93","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1086\/315372","volume":"181","author":"J Somani","year":"2000","unstructured":"Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant chlamydia trachomatis associated with clinical treatment failure. J Infect Dis. 2000;181(4):1421\u20137.","journal-title":"J Infect Dis"},{"key":"722_CR94","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ijid.2020.03.015","volume":"96","author":"L Shao","year":"2020","unstructured":"Shao L, You C, Cao J, Jiang Y, Liu Y, Liu Q. High treatment failure rate is better explained by resistance gene detection than by minimum inhibitory concentration in patients with urogenital Chlamydia trachomatis infection. Int J Infect Dis. 2020;96:121\u20137.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"722_CR95","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1159\/000314998","volume":"56","author":"AR Bhengraj","year":"2010","unstructured":"Bhengraj AR, Vardhan H, Srivastava P, Salhan S, Mittal A. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India. Chemotherapy. 2010;56(5):371\u20137.","journal-title":"Chemotherapy"},{"issue":"7","key":"722_CR96","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/00007435-199808000-00005","volume":"25","author":"JC Lefevre","year":"1998","unstructured":"Lefevre JC, Lepargneur JP. Comparative in vitro susceptibility of a tetracycline-resistant Chlamydia trachomatis strain isolated in Toulouse (France). Sex Transm Dis. 1998;25(7):350\u20132.","journal-title":"Sex Transm Dis"},{"issue":"4","key":"722_CR97","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1439-0272.2009.01019.x","volume":"42","author":"H Zhu","year":"2010","unstructured":"Zhu H, Wang HP, Jiang Y, Hou SP, Liu YJ, Liu QZ. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in Chlamydia trachomatis strains selected in vitro by macrolide passage. Andrologia. 2010;42(4):274\u201380.","journal-title":"Andrologia"},{"issue":"7","key":"722_CR98","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1101\/gr.212647.116","volume":"27","author":"J Hadfield","year":"2017","unstructured":"Hadfield J, Harris SR, Seth-Smith HMB, Parmar S, Andersson P, Giffard PM, et al. Comprehensive global genome dynamics of Chlamydia trachomatis show ancient diversification followed by contemporary mixing and recent lineage expansion. Genome Res. 2017;27(7):1220\u20139.","journal-title":"Genome Res"},{"issue":"9","key":"722_CR99","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jiac.2016.06.010","volume":"22","author":"S Takahashi","year":"2016","unstructured":"Takahashi S, Hamasuna R, Yasuda M, Ishikawa K, Hayami H, Uehara S, et al. Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan. J Infect Chemother. 2016;22(9):581\u20136.","journal-title":"J Infect Chemother"},{"issue":"1","key":"722_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jiac.2021.09.012","volume":"28","author":"S Takahashi","year":"2022","unstructured":"Takahashi S, Yasuda M, Wada K, Matsumoto M, Hayami H, Kobayashi K, et al. Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan: comparison with the first surveillance report. J Infect Chemother. 2022;28(1):1\u20135.","journal-title":"J Infect Chemother"},{"issue":"11","key":"722_CR101","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1128\/AAC.49.11.4804-4806.2005","volume":"49","author":"AW Solomon","year":"2005","unstructured":"Solomon AW, Mohammed Z, Massae PA, Shao JF, Foster A, Mabey DC, et al. Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. Antimicrob Agents Chemother. 2005;49(11):4804\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"722_CR102","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/infdis\/jiu046","volume":"210","author":"SK West","year":"2014","unstructured":"West SK, Moncada J, Munoz B, Mkocha H, Storey P, Hardick J, et al. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control? J Infect Dis. 2014;210(1):65\u201371.","journal-title":"J Infect Dis"},{"issue":"9","key":"722_CR103","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2217\/fmb.10.96","volume":"5","author":"KM Sandoz","year":"2010","unstructured":"Sandoz KM, Rockey DD. Antibiotic resistance in Chlamydiae. Future Microbiol. 2010;5(9):1427\u201342.","journal-title":"Future Microbiol"},{"issue":"26","key":"722_CR104","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1056\/NEJMoa1502599","volume":"373","author":"WM Geisler","year":"2015","unstructured":"Geisler WM, Uniyal A, Lee JY, Lensing SY, Johnson S, Perry RCW, et al. Azithromycin versus doxycycline for urogenital Chlamydia trachomatis infection. N Engl J Med. 2015;373(26):2512\u201321.","journal-title":"N Engl J Med"},{"issue":"9","key":"722_CR105","first-page":"603","volume":"17","author":"F Mohammadzadeh","year":"2019","unstructured":"Mohammadzadeh F, Dolatian M, Jorjani M, Afrakhteh M, Majd HA, Abdi F, et al. Urogenital Chlamydia trachomatis treatment failure with azithromycin: A meta-analysis. Int J Reprod Biomed. 2019;17(9):603\u201320.","journal-title":"Int J Reprod Biomed"},{"issue":"2","key":"722_CR106","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/cid\/ciu220","volume":"59","author":"FYS Kong","year":"2014","unstructured":"Kong FYS, Tabrizi SN, Law M, Vodstrcil LA, Chen M, Fairley CK, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;59(2):193\u2013205.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"722_CR107","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/ciq074","volume":"52","author":"JR Schwebke","year":"2011","unstructured":"Schwebke JR, Rompalo A, Taylor S, Sena AC, Martin DH, Lopez LM, et al. Re-evaluating the treatment of nongonococcal urethritis: Emphasizing emerging pathogens\u2013a randomized clinical trial. Clin Infect Dis. 2011;52(2):163\u201370.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"722_CR108","doi-asserted-by":"publisher","first-page":"e37778","DOI":"10.1371\/journal.pone.0037778","volume":"7","author":"J Walker","year":"2012","unstructured":"Walker J, Tabrizi SN, Fairley CK, Chen MY, Bradshaw CS, Twin J, et al. Chlamydia trachomatis incidence and re-infection among young women\u2013behavioural and microbiological characteristics. PLoS ONE. 2012;7(5):e37778.","journal-title":"PLoS ONE"},{"issue":"2","key":"722_CR109","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/OLQ.0000000000000088","volume":"41","author":"CM Khosropour","year":"2014","unstructured":"Khosropour CM, Dombrowski JC, Barbee LA, Manhart LE, Golden MR. Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: a retrospective cohort study. Sex Transm Dis. 2014;41(2):79\u201385.","journal-title":"Sex Transm Dis"},{"issue":"5","key":"722_CR110","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/cid\/ciab153","volume":"73","author":"JC Dombrowski","year":"2021","unstructured":"Dombrowski JC, Wierzbicki MR, Newman LM, Powell JA, Miller A, Dithmer D, et al. Doxycycline versus azithromycin for the treatment of rectal chlamydia in men who have sex with men: A randomized controlled trial. Clin Infect Dis. 2021;73(5):824\u201331.","journal-title":"Clin Infect Dis"},{"issue":"25","key":"722_CR111","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1056\/NEJMoa2031631","volume":"384","author":"A Lau","year":"2021","unstructured":"Lau A, Kong FYS, Fairley CK, Templeton DJ, Amin J, Phillips S, et al. Azithromycin or doxycycline for asymptomatic rectal Chlamydia trachomatis. N Engl J Med. 2021;384(25):2418\u201327.","journal-title":"N Engl J Med"},{"issue":"2","key":"722_CR112","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/jac\/dkx392","volume":"73","author":"C Foschi","year":"2018","unstructured":"Foschi C, Salvo M, Cevenini R, Marangoni A. Chlamydia trachomatis antimicrobial susceptibility in colorectal and endocervical cells. J Antimicrob Chemother. 2018;73(2):409\u201313.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"722_CR113","doi-asserted-by":"publisher","first-page":"e00203","DOI":"10.1128\/CVI.00203-17","volume":"24","author":"SS Witkin","year":"2017","unstructured":"Witkin SS, Minis E, Athanasiou A, Leizer J, Linhares IM. Chlamydia trachomatis: The persistent pathogen. Clin Vaccine Immunol. 2017;24(10):e00203\u201317. https:\/\/doi.org\/10.1128\/CVI.00203-17.","journal-title":"Clin Vaccine Immunol"},{"key":"722_CR114","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.3389\/fmicb.2018.03101","volume":"9","author":"ME Panzetta","year":"2018","unstructured":"Panzetta ME, Valdivia RH, Saka HA. Chlamydia persistence: A survival strategy to evade antimicrobial effects in-vitro and in-vivo. Front Microbiol. 2018;9:3101.","journal-title":"Front Microbiol"},{"issue":"3","key":"722_CR115","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1128\/AAC.02097-13","volume":"58","author":"R Phillips-Campbell","year":"2014","unstructured":"Phillips-Campbell R, Kintner J, Schoborg RV. Induction of the Chlamydia muridarum stress\/persistence response increases azithromycin treatment failure in a murine model of infection. Antimicrob Agents Chemother. 2014;58(3):1782\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"722_CR116","doi-asserted-by":"publisher","first-page":"104347","DOI":"10.1016\/j.micpath.2020.104347","volume":"147","author":"A Marangoni","year":"2020","unstructured":"Marangoni A, Zalambani C, Marziali G, Salvo M, Fato R, Foschi C, et al. Low-dose doxycycline induces Chlamydia trachomatis persistence in HeLa cells. Microb Pathog. 2020;147:104347.","journal-title":"Microb Pathog"},{"key":"722_CR117","doi-asserted-by":"publisher","unstructured":"Xue Y, Zheng H, Mai Z, Qin X, Chen W, Huang T, et al. An in vitro model of azithromycin-induced persistent chlamydia trachomatis infection. FEMS Microbiol Lett. 2017;364(14). https:\/\/doi.org\/10.1093\/femsle\/fnx145.","DOI":"10.1093\/femsle\/fnx145"},{"issue":"12","key":"722_CR118","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1086\/593188","volume":"47","author":"JS Jensen","year":"2008","unstructured":"Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. Azithromycin treatment failure in mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis. 2008;47(12):1546\u201353.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"722_CR119","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/cid\/civ644","volume":"61","author":"A Lau","year":"2015","unstructured":"Lau A, Bradshaw CS, Lewis D, Fairley CK, Chen MY, Kong FY, et al. The efficacy of azithromycin for the treatment of genital mycoplasma genitalium: A systematic review and meta-analysis. Clin Infect Dis. 2015;61(9):1389\u201399.","journal-title":"Clin Infect Dis"},{"key":"722_CR120","doi-asserted-by":"publisher","unstructured":"Chua T, Vodstrcil LA, Murray GL, Plummer E, Jensen JS, Unemo M, Chow EPF, Low N, Whiley DM, Sweeney EL, Hocking JS, Danielewski JA, Garland SM, Fairley CK, Zhang L, Bradshaw C, Machalek DA. Evolving patterns of macrolide and fluoroquinolone resistance in mycoplasma genitalium: an updated global systematic review and meta-analysis. Pre-Print available at SSRN: https:\/\/ssrn.com\/abstract=4764790 or https:\/\/doi.org\/10.2139\/ssrn.4764790 Accessed November 6, 2024. 2024.","DOI":"10.2139\/ssrn.4764790"},{"issue":"7","key":"722_CR121","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3201\/eid1207.051558","volume":"12","author":"CS Bradshaw","year":"2006","unstructured":"Bradshaw CS, Jensen JS, Tabrizi SN, Read TR, Garland SM, Hopkins CA, et al. Azithromycin failure in mycoplasma genitalium urethritis. Emerg Infect Dis. 2006;12(7):1149\u201352.","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"722_CR122","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1177\/0956462416688562","volume":"28","author":"Y Li","year":"2017","unstructured":"Li Y, Le WJ, Li S, Cao YP, Su XH. Meta-analysis of the efficacy of moxifloxacin in treating mycoplasma genitalium infection. Int J STD AIDS. 2017;28(11):1106\u201314. https:\/\/doi.org\/10.1177\/0956462416688562.","journal-title":"Int J STD AIDS"},{"issue":"5","key":"722_CR123","doi-asserted-by":"publisher","first-page":"e0027822","DOI":"10.1128\/aac.00278-22","volume":"66","author":"GL Murray","year":"2022","unstructured":"Murray GL, Bodiyabadu K, Vodstrcil LA, Machalek DA, Danielewski J, Plummer EL, et al. parC variants in mycoplasma genitalium: Trends over time and association with moxifloxacin failure. Antimicrob Agents Chemother. 2022;66(5):e0027822.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"722_CR124","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/cid\/ciad057","volume":"72","author":"GL Murray","year":"2023","unstructured":"Murray GL, Plummer EL, Bodiyabadu K, Vodstrcil LA, Huaman JL, Danielewski JA, et al. gyrA mutations in Mycoplasma genitalium and their contribution to moxifloxacin failure: Time for the next generation of resistance-guided therapy. Clin Infect Dis. 2023;72(12):2187\u201395. https:\/\/doi.org\/10.1093\/cid\/ciad057.","journal-title":"Clin Infect Dis."},{"issue":"4","key":"722_CR125","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1093\/cid\/ciy477","volume":"68","author":"TRH Read","year":"2019","unstructured":"Read TRH, Fairley CK, Murray GL, Jensen JS, Danielewski J, Worthington K, et al. Outcomes of resistance-guided sequential treatment of mycoplasma genitalium infections: A prospective evaluation. Clin Infect Dis. 2019;68(4):554\u201360.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"722_CR126","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/cid\/ciz1031","volume":"71","author":"D Durukan","year":"2020","unstructured":"Durukan D, Read TRH, Murray G, Doyle M, Chow EPF, Vodstrcil LA, et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and Doxycycline-2.5 g azithromycin for the treatment of mycoplasma genitalium infection: Efficacy and tolerability. Clin Infect Dis. 2020;71(6):1461\u20138.","journal-title":"Clin Infect Dis"},{"key":"722_CR127","unstructured":"World health organization. guidelines for the management of symptomatic sexually transmitted infections. June 2021. Availablet at: https:\/\/iris.who.int\/bitstream\/handle\/10665\/342523\/9789240024168-eng.pdf?sequence=1 Accessed November 2, 2024."},{"issue":"5","key":"722_CR128","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/cid\/ciab1058","volume":"75","author":"LA Vodstrcil","year":"2022","unstructured":"Vodstrcil LA, Plummer EL, Doyle M, Murray GL, Bodiyabadu K, Jensen JS, et al. Combination therapy for mycoplasma genitalium, and new insights into the utility of parc mutant detection to improve cure. Clin Infect Dis. 2022;75(5):813\u201323.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"722_CR129","doi-asserted-by":"publisher","first-page":"ofad427","DOI":"10.1093\/ofid\/ofad427","volume":"10","author":"EJ Clarke","year":"2023","unstructured":"Clarke EJ, Vodstrcil LA, Plummer EL, Aguirre I, Samra RS, Fairley CK, et al. Efficacy of minocycline for the treatment of mycoplasma genitalium. Open Forum Infect Dis. 2023;10(8):ofad427.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"722_CR130","doi-asserted-by":"publisher","first-page":"ofaa291","DOI":"10.1093\/ofid\/ofaa291","volume":"7","author":"M Doyle","year":"2020","unstructured":"Doyle M, Vodstrcil L, Plummer EP, Aguirre I, Fairley CK, Bradshaw CS. Non-quinolone options for the treatment of mycoplasma genitalium in the era of increased resistance. Open Forum Infect Dis. 2020;7(8):ofaa291. https:\/\/doi.org\/10.1093\/ofid\/ofaa291.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"722_CR131","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3201\/eid2402.170902","volume":"24","author":"TRH Read","year":"2018","unstructured":"Read TRH, Jensen JS, Fairley CK, Grant M, Danielewski JA, Su J, et al. Use of pristinamycin for macrolide-resistant mycoplasma genitalium infection. Emerg Infect Dis. 2018;24(2):328\u201335.","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"722_CR132","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/jac\/dky022","volume":"73","author":"AC Damiao Gouveia","year":"2018","unstructured":"Damiao Gouveia AC, Unemo M, Jensen JS. In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains. J Antimicrob Chemother. 2018;73(5):1291\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"722_CR133","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1080\/22221751.2020.1775498","volume":"9","author":"JS Jensen","year":"2020","unstructured":"Jensen JS, Norgaard C, Scangarella-Oman N, Unemo M. In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium. Emerg Microbes Infect. 2020;9(1):1388\u201392.","journal-title":"Emerg Microbes Infect"},{"issue":"12","key":"722_CR134","doi-asserted-by":"publisher","first-page":"e0010063","DOI":"10.1371\/journal.pntd.0010063","volume":"15","author":"NAP Lieberman","year":"2021","unstructured":"Lieberman NAP, Lin MJ, Xie H, Shrestha L, Nguyen T, Huang ML, et al. Treponema pallidum genome sequencing from six continents reveals variability in vaccine candidate genes and dominance of Nichols clade strains in Madagascar. PLoS Negl Trop Dis. 2021;15(12):e0010063.","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"722_CR135","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1016\/S2666-5247(22)00035-0","volume":"3","author":"ML Taouk","year":"2022","unstructured":"Taouk ML, Taiaroa G, Pasricha S, Herman S, Chow EPF, Azzatto F, et al. Characterisation of treponema pallidum lineages within the contemporary syphilis outbreak in Australia: A genomic epidemiological analysis. Lancet Microbe. 2022;3(6):e417\u201326.","journal-title":"Lancet Microbe"},{"issue":"46","key":"722_CR136","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.15585\/mmwr.mm7246e1","volume":"72","author":"R McDonald","year":"2023","unstructured":"McDonald R, O\u2019Callaghan K, Torrone E, Barbee L, Grey J, Jackson D, et al. Vital signs: Missed opportunities for preventing congenital syphilis - United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(46):1269\u201374.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"722_CR137","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41564-021-01000-z","volume":"6","author":"MA Beale","year":"2021","unstructured":"Beale MA, Marks M, Cole MJ, Lee MK, Pitt R, Ruis C, et al. Global phylogeny of Treponema pallidum lineages reveals recent expansion and spread of contemporary syphilis. Nat Microbiol. 2021;6(12):1549\u201360.","journal-title":"Nat Microbiol"},{"issue":"Suppl 2","key":"722_CR138","doi-asserted-by":"publisher","first-page":"S314","DOI":"10.1093\/clinids\/7-Supplement_2.S314","volume":"7","author":"JT Stapleton","year":"1985","unstructured":"Stapleton JT, Stamm LV, Bassford PJ. Jr. Potential for development of antibiotic resistance in pathogenic treponemes. Rev Infect Dis. 1985;7(Suppl 2):S314\u20137.","journal-title":"Rev Infect Dis"},{"issue":"2","key":"722_CR139","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1128\/AAC.32.2.164","volume":"32","author":"LV Stamm","year":"1988","unstructured":"Stamm LV, Stapleton JT, Bassford PJ. Jr. in vitro assay to demonstrate high-level erythromycin resistance of a clinical isolate of treponema pallidum. Antimicrob Agents Chemother. 1988;32(2):164\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"722_CR140","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/OLQ.0000000000000486","volume":"43","author":"BJ Molini","year":"2016","unstructured":"Molini BJ, Tantalo LC, Sahi SK, Rodriguez VI, Brandt SL, Fernandez MC, et al. Macrolide resistance in treponema pallidum correlates with 23S rDNA mutations in recently isolated clinical strains. Sex Transm Dis. 2016;43(9):579\u201383.","journal-title":"Sex Transm Dis"},{"issue":"Pt 6","key":"722_CR141","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1099\/jmm.0.007542-0","volume":"58","author":"P Matejkova","year":"2009","unstructured":"Matejkova P, Flasarova M, Zakoucka H, Borek M, Kremenova S, Arenberger P, et al. Macrolide treatment failure in a case of secondary syphilis: A novel A2059G mutation in the 23S rRNA gene of treponema pallidum subsp. pallidum. J Med Microbiol. 2009;58(Pt 6):832\u20136.","journal-title":"J Med Microbiol"},{"issue":"2","key":"722_CR142","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa040216","volume":"351","author":"SA Lukehart","year":"2004","unstructured":"Lukehart SA, Godornes C, Molini BJ, Sonnett P, Hopkins S, Mulcahy F, et al. Macrolide resistance in treponema pallidum in the United States and Ireland. N Engl J Med. 2004;351(2):154\u20138.","journal-title":"N Engl J Med"},{"issue":"10","key":"722_CR143","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/OLQ.0b013e31826f36de","volume":"39","author":"AGP Workgroup","year":"2012","unstructured":"Workgroup AGP. Prevalence of the 23S rRNA A2058G point mutation and molecular subtypes in Treponema pallidum in the United States, 2007 to 2009. Sex Transm Dis. 2012;39(10):794\u20138.","journal-title":"Sex Transm Dis"},{"issue":"22","key":"722_CR144","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMc2314441","volume":"390","author":"NAP Lieberman","year":"2024","unstructured":"Lieberman NAP, Reid TB, Cannon CA, Nunley BE, Berzkalns A, Cohen SE, et al. Near-universal resistance to macrolides of treponema pallidum in North America. N Engl J Med. 2024;390(22):2127\u20138.","journal-title":"N Engl J Med"},{"issue":"12","key":"722_CR145","doi-asserted-by":"publisher","first-page":"e994","DOI":"10.1016\/S2666-5247(23)00219-7","volume":"4","author":"LC Tantalo","year":"2023","unstructured":"Tantalo LC, Lieberman NAP, Perez-Mana C, Suner C, Vall Mayans M, Ubals M, et al. Antimicrobial susceptibility of treponema pallidum subspecies pallidum: An in-vitro study. Lancet Microbe. 2023;4(12):e994\u20131004.","journal-title":"Lancet Microbe"},{"issue":"10","key":"722_CR146","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.amjmed.2008.04.042","volume":"121","author":"T Wong","year":"2008","unstructured":"Wong T, Singh AE, De P. Primary syphilis: Serological treatment response to doxycycline\/tetracycline versus benzathine penicillin. Am J Med. 2008;121(10):903\u20138.","journal-title":"Am J Med"},{"issue":"6","key":"722_CR147","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1086\/500406","volume":"42","author":"KG Ghanem","year":"2006","unstructured":"Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis. 2006;42(6):e45\u20139.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"722_CR148","first-page":"119","volume":"27","author":"V Harshan","year":"1982","unstructured":"Harshan V, Jayakumar W. Doxycycline in early syphilis: a long term follow up. Indian J Dermatol. 1982;27(4):119\u201324.","journal-title":"Indian J Dermatol"},{"issue":"1","key":"722_CR149","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7164\/antibiotics.33.18","volume":"33","author":"Y Onoda","year":"1980","unstructured":"Onoda Y. [Therapeutic effect of oral doxycycline on syphilis (author\u2019s transl]. Jpn J Antibiot. 1980;33(1):18\u201328.","journal-title":"Jpn J Antibiot"},{"key":"722_CR150","doi-asserted-by":"publisher","unstructured":"Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. Microbiol Spectr. 2016;4(2). https:\/\/doi.org\/10.1128\/microbiolspec.VMBF-0016-2015","DOI":"10.1128\/microbiolspec.VMBF-0016-2015"},{"key":"722_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jgar.2017.02.003","volume":"9","author":"H Xiao","year":"2017","unstructured":"Xiao H, Li Z, Li F, Wen J, Liu D, Du W, et al. Preliminary study of tetracycline resistance genes in Treponema pallidum. J Glob Antimicrob Resist. 2017;9:1\u20132.","journal-title":"J Glob Antimicrob Resist"},{"key":"722_CR152","doi-asserted-by":"publisher","first-page":"jiae381","DOI":"10.1093\/infdis\/jiae381","volume":"27","author":"LC Tantalo","year":"2024","unstructured":"Tantalo LC, Luetkemeyer A, Lieberman NAP, Nunley BE, Avendano C, Greninger AL, et al. Long-term in vitro exposure of Treponema pallidum to sub-bactericidal doxycycline did not induce resistance: Implications for doxy-PEP and syphilis. J Infect Dis. 2024;27:jiae381. https:\/\/doi.org\/10.1093\/infdis\/jiae381.","journal-title":"J Infect Dis"},{"issue":"10","key":"722_CR153","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1001\/archderm.137.10.1374","volume":"137","author":"VG Fowler Jr","year":"2001","unstructured":"Fowler VG Jr, Maxwell GL, Myers SA, Shea CR, Livengood CN 3, Prieto VG, et al. Failure of benzathine penicillin in a case of seronegative secondary syphilis in a patient with acquired immunodeficiency syndrome: Case report and review of the literature. Arch Dermatol. 2001;137(10):1374\u20136.","journal-title":"Arch Dermatol"},{"issue":"7","key":"722_CR154","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/jama.2009.143","volume":"301","author":"JM Douglas","year":"2009","unstructured":"Douglas JM. Jr. Penicillin treatment of syphilis: Clearing away the shadow on the land. JAMA. 2009;301(7):769\u201371.","journal-title":"JAMA"},{"issue":"9","key":"722_CR155","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJMra1901593","volume":"382","author":"KG Ghanem","year":"2020","unstructured":"Ghanem KG, Ram S, Rice PA. The modern epidemic of Syphilis. N Engl J Med. 2020;382(9):845\u201354.","journal-title":"N Engl J Med"},{"issue":"28","key":"722_CR156","doi-asserted-by":"publisher","first-page":"42904","DOI":"10.18632\/oncotarget.10154","volume":"7","author":"J Sun","year":"2016","unstructured":"Sun J, Meng Z, Wu K, Liu B, Zhang S, Liu Y, et al. Tracing the origin of Treponema pallidum in China using next-generation sequencing. Oncotarget. 2016;7(28):42904\u201318.","journal-title":"Oncotarget"},{"issue":"15","key":"722_CR157","doi-asserted-by":"publisher","first-page":"14917","DOI":"10.1074\/jbc.M400666200","volume":"279","author":"JY Cha","year":"2004","unstructured":"Cha JY, Ishiwata A, Mobashery S. A novel beta-lactamase activity from a penicillin-binding protein of Treponema pallidum and why syphilis is still treatable with penicillin. J Biol Chem. 2004;279(15):14917\u201321.","journal-title":"J Biol Chem"},{"issue":"Suppl2","key":"722_CR158","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1093\/cid\/ciac030","volume":"74","author":"PJ Kissinger","year":"2022","unstructured":"Kissinger PJ, Gaydos CA, Sena AC, Scott McClelland R, Soper D, Secor WE, et al. Diagnosis and management of trichomonas vaginalis: Summary of evidence reviewed for the 2021 centers for disease control and prevention sexually transmitted infections treatment guidelines. Clin Infect Dis. 2022;74(Suppl2):S152\u201361.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"722_CR159","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S1473-3099(18)30423-7","volume":"18","author":"P Kissinger","year":"2018","unstructured":"Kissinger P, Muzny CA, Mena LA, Lillis RA, Schwebke JR, Beauchamps L, et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(11):1251\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"14","key":"722_CR160","first-page":"665","volume":"86","author":"SC Robinson","year":"1962","unstructured":"Robinson SC. Trichomonal vaginitis resistant to metranidazole. Can Med Assoc J. 1962;86(14):665.","journal-title":"Can Med Assoc J"},{"key":"722_CR161","unstructured":"Pearlman RLVGO, Kissinger PJ, Secor WE, Muzny CA. Treatment of trichomonas vaginalis in women in the setting of 5-nitroimidazole drug resistance. Oral presentation (Abstract 461) in the infectious diseases I session at the 2022 AFMR-SRM Southern regional meeting in New Orleans, LA on February 11, 2022."},{"issue":"6","key":"722_CR162","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3201\/eid1806.111590","volume":"18","author":"RD Kirkcaldy","year":"2012","unstructured":"Kirkcaldy RD, Augostini P, Asbel LE, Bernstein KT, Kerani RP, Mettenbrink CJ, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD surveillance network, 2009\u20132010. Emerg Infect Dis. 2012;18(6):939\u201343.","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"722_CR163","doi-asserted-by":"publisher","first-page":"e02329","DOI":"10.1128\/AAC.02329-17","volume":"62","author":"AP Ghosh","year":"2018","unstructured":"Ghosh AP, Aycock C, Schwebke JR. In vitro study of the susceptibility of clinical isolates of trichomonas vaginalis to metronidazole and secnidazole. Antimicrob Agents Chemother. 2018;62(4):e02329\u201317. https:\/\/doi.org\/10.1128\/AAC.02329-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"13","key":"722_CR164","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1017\/S0031182020001237","volume":"147","author":"KJ Graves","year":"2020","unstructured":"Graves KJ, Novak J, Secor WE, Kissinger PJ, Schwebke JR, Muzny CA. A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in Trichomonas vaginalis. Parasitology. 2020;147(13):1383\u201391.","journal-title":"Parasitology"},{"issue":"5","key":"722_CR165","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/pathogens12050692","volume":"12","author":"KJ Graves","year":"2023","unstructured":"Graves KJ, Reily C, Tiwari HK, Srinivasasainagendra V, Secor WE, Novak J, et al. Identification of trichomonas vaginalis 5-nitroimidazole resistance targets. Pathogens. 2023;12(5):692. https:\/\/doi.org\/10.3390\/pathogens12050692.","journal-title":"Pathogens"},{"issue":"2","key":"722_CR166","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1128\/AAC.00909-08","volume":"53","author":"D Pal","year":"2009","unstructured":"Pal D, Banerjee S, Cui J, Schwartz A, Ghosh SK, Samuelson J, Giardia. Entamoeba, and trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob Agents Chemother. 2009;53(2):458\u201364.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"722_CR167","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/jac\/5.3.315","volume":"5","author":"DI Edwards","year":"1979","unstructured":"Edwards DI, Thompson EJ, Tomusange J, Shanson D. Inactivation of metronidazole by aerobic organisms. J Antimicrob Chemother. 1979;5(3):315\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"722_CR168","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/jac\/10.2.84","volume":"10","author":"HR Ingham","year":"1982","unstructured":"Ingham HR, Sisson PR, Selkon JB. Interactions between micro-organisms and metronidazole. J Antimicrob Chemother. 1982;10(2):84\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"9\u201310","key":"722_CR169","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.resmic.2017.03.005","volume":"168","author":"R Fichorova","year":"2017","unstructured":"Fichorova R, Fraga J, Rappelli P, Fiori PL. Trichomonas vaginalis infection in symbiosis with Trichomonasvirus and Mycoplasma. Res Microbiol. 2017;168(9\u201310):882\u201391.","journal-title":"Res Microbiol"},{"issue":"5","key":"722_CR170","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/infdis\/153.5.948","volume":"153","author":"JG Lossick","year":"1986","unstructured":"Lossick JG, Muller M, Gorrell TE. In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis. 1986;153(5):948\u201355.","journal-title":"J Infect Dis"},{"issue":"4","key":"722_CR171","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1128\/AAC.47.4.1407-1409.2003","volume":"47","author":"AL Crowell","year":"2003","unstructured":"Crowell AL, Sanders-Lewis KA, Secor WE. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother. 2003;47(4):1407\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"722_CR172","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF01937754","volume":"32","author":"JG Meingassner","year":"1976","unstructured":"Meingassner JG, Mieth H. Cross-resistance of trichomonads to 5-nitroimidazole-derivatives. Experientia. 1976;32(2):183\u20134.","journal-title":"Experientia"},{"issue":"12","key":"722_CR173","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0956462414523260","volume":"25","author":"FO Otieno","year":"2014","unstructured":"Otieno FO, Ndivo R, Oswago S, Ondiek J, Pals S, McLellan-Lemal E, et al. Evaluation of syndromic management of sexually transmitted infections within the kisumu incidence cohort study. Int J STD AIDS. 2014;25(12):851\u20139.","journal-title":"Int J STD AIDS"},{"issue":"6","key":"722_CR174","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S1473-3099(18)30724-2","volume":"19","author":"MC Verwijs","year":"2019","unstructured":"Verwijs MC, Agaba SK, Sumanyi JC, Umulisa MM, Mwambarangwe L, Musengamana V, et al. Targeted point-of-care testing compared with syndromic management of urogenital infections in women (WISH): a cross-sectional screening and diagnostic accuracy study. Lancet Infect Dis. 2019;19(6):658\u201369.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"722_CR175","first-page":"169passim","volume":"110","author":"J Portnoy","year":"1974","unstructured":"Portnoy J, Mendelson J, Clecner B, Heisler L. Asymptomatic gonorrhea in the male. Can Med Assoc J. 1974;110(2):169passim.","journal-title":"Can Med Assoc J"},{"issue":"3","key":"722_CR176","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJM197401172900301","volume":"290","author":"HH Handsfield","year":"1974","unstructured":"Handsfield HH, Lipman TO, Harnisch JP, Tronca E, Holmes KK. Asymptomatic gonorrhea in men. Diagnosis, natural course, prevalence and significance. N Engl J Med. 1974;290(3):117\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"722_CR177","first-page":"277","volume":"40","author":"CL Ventola","year":"2015","unstructured":"Ventola CL. The antibiotic resistance crisis: part 1: Causes and threats. P T. 2015;40(4):277\u201383.","journal-title":"P T"},{"issue":"1","key":"722_CR178","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/nyas.13871","volume":"1435","author":"TD Mortimer","year":"2019","unstructured":"Mortimer TD, Grad YH. Applications of genomics to slow the spread of multidrug-resistant Neisseria gonorrhoeae. Ann N Y Acad Sci. 2019;1435(1):93\u2013109.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"722_CR179","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1473-3099(23)00683-7","volume":"24","author":"M Ubals","year":"2024","unstructured":"Ubals M, Nadal-Baron P, Arando M, Rivero A, Mendoza A, Descalzo Jorro V, et al. Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2024;24(4):404\u201316.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"722_CR180","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1473-3099(23)00693-X","volume":"24","author":"C Stafylis","year":"2024","unstructured":"Stafylis C, Klausner JD. Repurposing antibiotics to treat syphilis. Lancet Infect Dis. 2024;24(4):335\u20136.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"722_CR181","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/cid\/ciab187","volume":"73","author":"C Stafylis","year":"2021","unstructured":"Stafylis C, Keith K, Mehta S, Tellalian D, Burian P, Millner C, et al. Clinical efficacy of cefixime for the treatment of early syphilis. Clin Infect Dis. 2021;73(5):907\u201310.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"722_CR182","doi-asserted-by":"publisher","first-page":"e01153","DOI":"10.1128\/mBio.01153-18","volume":"9","author":"DG Edmondson","year":"2018","unstructured":"Edmondson DG, Hu B, Norris SJ. Long-term in vitro culture of the syphilis spirochete treponema pallidum subsp pallidum. mBio. 2018;9(3):e01153\u201318. https:\/\/doi.org\/10.1128\/mBio.01153-18.","journal-title":"mBio"},{"issue":"12","key":"722_CR183","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3390\/antibiotics9120918","volume":"9","author":"K Tiseo","year":"2020","unstructured":"Tiseo K, Huber L, Gilbert M, Robinson TP, Van Boeckel TP. Global trends in antimicrobial use in food animals from 2017 to 2030. Antibiot (Basel). 2020;9(12):918. https:\/\/doi.org\/10.3390\/antibiotics9120918.","journal-title":"Antibiot (Basel)"},{"issue":"11","key":"722_CR184","doi-asserted-by":"publisher","first-page":"6772","DOI":"10.1021\/acs.est.5b00729","volume":"49","author":"QQ Zhang","year":"2015","unstructured":"Zhang QQ, Ying GG, Pan CG, Liu YS, Zhao JL. Comprehensive evaluation of antibiotics emission and fate in the river basins of China: Source analysis, multimedia modeling, and linkage to bacterial resistance. Environ Sci Technol. 2015;49(11):6772\u201382.","journal-title":"Environ Sci Technol"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00722-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-025-00722-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00722-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:07:06Z","timestamp":1769605626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-025-00722-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":184,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1007\/s11904-025-00722-7","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"7 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.S.B. and S.P. have received funds from SpeeDx Inc., to study resistance-guided therapy. C.A.M has received grants to her institution from Abbott, BioNTech, Gilead, Lupin, and Visby. She also reports honorarium and\/or consulting fees from Cepheid, BioNTech, bioM\u00e9rieux, Visby, Elsevier, Merck Manuals, UpToDate, and Abbott. S.J.J. has received consulting fees from Preventx Inc. L.A.B. has received honorarium from Elsevier and UpToDate. The remaining authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}